Etanercept is safely used for treating psoriatic arthritis in a patient complicated with type 1 hereditary angioedema.
Hereditary angioedema (HAE) is a life-threatening disorder caused by deficiency or dysfunction of the C1 inhibitor protein. Patients with HAE are restricted in various medical treatments, which can induce an HAE attack. We herein report the first case of psoriatic arthritis (PSA) with type 1 HAE successfully treated with 25 mg of etanercept without HAE attack. Etanercept may represent a useful choice for treating patients with HAE accompanied by intractable PSA and rheumatoid arthritis (RA).
Department of Dermatology, Osaka University Graduate School of Medicine, Osaka, Japan.
Noriko
N
Umegaki
Masahiro
M
Kira
Takahiko
T
Horiuchi
Saori
S
Itoi
Mamori
M
Tani
Akinori
A
Yokomi
Atsushi
A
Tanemura
Hisaaki
H
Miyahara
Michiyo
M
Hatanaka
Hajime
H
Kitamura
Etsuko
E
Kitano
Ichiro
I
Katayama
D000328:Adult; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000150:complications / Q000188:drug therapy*; D000068800:Etanercept; D005260:Female; D056829:Hereditary Angioedema Types I and II / Q000150:complications*; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D016896:Treatment Outcome
D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept